As the mental health crisis reaches a critical stage, governments and institutions all over the world are looking at unconventional methods for treatment. Biotech companies are now using psychedelics to research solutions to treat depression, PTSD, suicidal tendencies while promoting general wellness.
Some of the companies that are leading the charge are:
Located in London, England, Compass Pathways is guided by their desire to discover effective solutions for mental health challenges. One of their major initiatives is developing psilocybin therapy for treatment-resistant depression (TRD). The company is currently running the world’s first large-scale psilocybin therapy clinical trial in 20 sites across Europe and North America. On March 23, the company announced that the US Patent and Trademark Office had granted it two new patents for synthetic psilocybin formulations they developed to treat major depressive disorder and treatment-resistant depression.
Jamaica-based biotech company Minerco Inc. is a vertically integrated publicly traded company focusing on cultivating, producing, researching, and distributing psilocybin mushrooms. They grow and develop their unique strain of mushrooms specific to Jamaica and also serve as a processing plant for growers that would like to convert their product into tablets, doses, and tinctures.
Mydecine Innovations Group
Located in Canada, Mydecine Innovations Group is an emerging biotech and life sciences company dedicated to developing and building a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. This company has access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada and a state-of-the-art mycology lab in Denver, CO.
Headquartered in New York, Seelos Therapeutics is a biopharmaceutical company that focuses on developing and advancing novel therapeutics for patients with central nervous system (CNS) disorders and other rare diseases. The company is currently conducting part one of its registrational Proof of Concept study of intranasal racemic ketamine for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder.
Located in Canada, Numinus Bioscience supports and expands psychedelic-assisted psychotherapies' safe, accessible, and evidence-based use.
The company holds a Controlled Drugs and Substances license to allow the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelic compounds and natural source materials like Psilocybe mushroom fruiting bodies and extracts, Psilocybin, Psilocin, Ketamine, LSD, DMT, and Mescaline.
Lab Management Software for Psychedelic Biotech Companies: Scispot.io
Scispot has become the primary lab management software of choice for numerous drug discovery biotechs, including psychedelic research companies.
Psychedelic research companies use Scispot's operating platform to manage their research projects, inventory, samples, and partners all in one spot. Request a demo to learn how you can accelerate your psychedelic research using Scispot.